Legend Biotech (LEGN) Total Current Liabilities (2019 - 2026)

Legend Biotech (LEGN) has reported Total Current Liabilities for 8 consecutive years, with $509.1 million the latest figure, recorded in Q1 2026.

• Quarterly Total Current Liabilities rose 117.22% year-over-year to $509.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $509.1 million (up 117.22% YoY) and the FY2025 annual result came in at $636.4 million, up 129.17% from the prior year.
• Total Current Liabilities retreated to $509.1 million in Q1 2026 per LEGN's latest filing, from $636.4 million in the prior quarter.
• Over the last five years, Total Current Liabilities for LEGN reached as high as $636.4 million in Q4 2025 and fell as low as $175.2 million in Q3 2023.
• A 5-year average of $301.7 million and a median of $265.5 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities soared 154433.99% — and 2023, when it slipped 27.32%.
• Year by year, Total Current Liabilities stood at $297.8 million in 2022, then retreated by 27.32% to $216.4 million in 2023, then advanced by 28.32% to $277.7 million in 2024, then soared by 129.17% to $636.4 million in 2025, then fell by 20.0% to $509.1 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $509.1 million, $636.4 million, and $433.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.